The Use of Genomics to Guide the Choice of Targeted Treatment for Patients with Relapsed Multiple Myeloma

Share
Print

Full Title

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-Arm Trial of Targeted Agents Alone or in Combination with a Backbone Regimen)

Purpose

In this study, researchers are evaluating the treatment of patients with multiple myeloma and other plasma cell cancers using drug combinations matched to genetic mutations in their cancers. The study groups include:

  • Treatment with the combination of abemaciclib, dexamethasone, pomalidomide, and ixazomib for patients with CCND1-activating mutations.
  • The combination of enasidenib, dexamethasone, pomalidomide, and ixazomib for patients with IDH2-activating mutations.
  • Cobimetinib, dexamethasone, pomalidomide, and ixazomib for patients with RAF/RAS mutations.
  • Venetoclax, dexamethasone, pomalidomide, and ixazomib for patients with a gene rearrangement called Translocation t (11;14).
  • Daratumumab, dexamethasone, pomalidomide, and ixazomib for patients with no genetic mutations in their cancers that can be targeted with the other study medications.

All of the medications given in this study are taken orally (by mouth), except for daratumumab, which is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have high-risk multiple myeloma or another plasma cell cancer that came back despite at least one but no more than three prior regimens of therapy.
  • Patients may not have previously received ixazomib/pomalidomide/dexamethasone therapy.
  • Patients should recover from the serious side effects of previous treatments before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. C. Ola Landgren at 212-639-5126.

Protocol

19-324

Phase

I/II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators